A Study of Quarterly Intravenous Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis.

N/ANo Longer AvailableNCT00493532

Hoffmann-La Roche

Overview

This single arm study will assess the efficacy and safety of quarterly intravenous Bonviva in women with post-menopausal osteoporosis. All patients will receive Bonviva 3mg i.v. every 3 months. The anticipated time on study treatment is 3-12 months, and the target sample size is 100 individuals.

Study Type

EXPANDED_ACCESS

Conditions

Postmenopausal Osteoporosis

Interventions

ibandronate [Bonviva/Boniva]DRUG

3mg iv every 3 months

Eligibility

Sex: FEMALEMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * post-menopausal women with osteoporosis; * \<=80 years of age; * naive to oral bisphosphonates, or have discontinued daily and/or weekly bisphosphonate treatment for \>1 year. Exclusion Criteria: * metabolic bone disease other than post-menopausal osteoporosis; * treatment with other drugs affecting bone metabolism within last 6 months; * previous or current malignant disease (except for adequately treated cancer in situ of the cervix, or basal or squamous cell skin cancer).

Locations (14)

Unnamed facility

Chai Yi, Taiwan

Unnamed facility

Changhua, Taiwan

Unnamed facility

Kaohsiung City, Taiwan

Unnamed facility

Kaohsiung City, Taiwan

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.